/PRNewswire/ FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced.
/PRNewswire/ FibroBiologics, a clinical-stage company developing fibroblast cell-based therapeutics for chronic diseases, today introduced its scientific.
Preeminent scientists join FibroBiologics to provide input for the growing clinical pipeline of cell therapies HOUSTON, Dec. 15, 2021 /PRNewswire/ FibroBiologics, a clinical-stage
Message :
Required fields AFM24 preclinical in vivo data will be presented as a poster Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15. In addition, early data from a Phase 1 study evaluating AFM13 preloaded